Osteopontin (OPN) Antibody and Recombinant Protein: Tools for Bone and Cancer Research

Concept: Molecular Characteristics and Physiological Functions of OPN

Osteopontin is a highly phosphorylated secreted glycoprotein and a member of the small integrin-binding ligand N-linked glycoprotein family, encoded by the SPP1 gene. The molecule ranges from approximately 44 to 75 kDa and contains an arginine-glycine-aspartate motif, a calcium-binding region, and multiple phosphorylation sites. These structural elements enable binding to a range of integrins, including alpha-v beta-1, alpha-v beta-3, alpha-v beta-5, alpha-4 beta-1, alpha-5 beta-1, alpha-8 beta-1, and alpha-9 beta-1, as well as CD44 variants, mediating cell-to-cell and cell-to-matrix interactions. Osteopontin is widely distributed in the human body, first identified in bone matrix and subsequently detected in kidney, blood vessels, immune cells, and mammary epithelium. Under normal conditions it participates in bone mineralization, tissue remodeling, immune regulation, and wound healing, while aberrant expression accompanies tumor progression, inflammatory disease, cardiovascular pathology, kidney stone formation, and autoimmune conditions.

Research Frontiers: OPN in Malignant Progression

Osteopontin overexpression has been documented across numerous cancer types, including head and neck carcinoma, osteosarcoma, hepatocellular carcinoma, non-small cell lung cancer, and esophageal squamous cell carcinoma, with expression levels correlating significantly with tumor aggressiveness, metastatic potential, and poor prognosis. A meta-analysis of fifty-one studies reported that tissue and plasma osteopontin expression was significantly elevated in head and neck carcinoma compared with controls, with a standardized mean difference of 0.98 and a 95 percent confidence interval of 0.47 to 1.49. High osteopontin levels predicted poorer survival, with hazard ratios of 2.00 for plasma and 2.71 for tissue. Mechanistically, osteopontin promotes malignant progression by activating PI3K-Akt, NF-κB, and MAPK signaling pathways, enhancing migration, invasion, and metastasis, inducing epithelial-mesenchymal transition, stimulating angiogenesis, modulating the immune microenvironment to evade surveillance, and increasing chemoresistance.

Splice Variants and Isoform-Specific Detection

The relationship between osteopontin splice variants and metastasis has attracted considerable research attention, with OPN-c particularly associated with high metastatic potential. Among the monoclonal antibodies developed against osteopontin, only specific clones such as 4G2B5 recognize OPN-c selectively, and this discriminating capacity positions them as candidate tools for prognosis assessment and high-metastasis detection. The functional divergence among osteopontin variants provides new targets for precision research while imposing higher demands on antibody development, since reagents must be validated for isoform discrimination rather than pan-osteopontin reactivity alone. Antibodies directed against individual functional domains, including the RGD sequence, calcium-binding region, and phosphorylation sites, extend this precision further by permitting independent interrogation of each domain's contribution, and they create openings for research strategies targeting defined osteopontin functions.

Discovery and Translational Research Applications

Osteopontin detection methodology has advanced rapidly from early immunohistochemistry and Western blot to current ELISA, immunofluorescence, and colloidal gold strip platforms, establishing the foundation for translational studies. Serum and plasma osteopontin measurement offers a non-invasive and convenient route for tumor screening, diagnostic evaluation, and prognosis assessment. Research has shown that serum osteopontin levels in patients with malignancy significantly exceed those of control groups, that preoperative or pre-treatment levels substantially exceed post-treatment values, and that concentrations correlate closely with lymph node involvement and distant metastasis. In non-small cell lung cancer, plasma osteopontin levels notably exceed those in benign pulmonary disease and healthy controls, with positive correlation to tumor stage and distant metastasis. In esophageal squamous cell carcinoma, a study of 103 patients reported preoperative plasma osteopontin values ranging from 82.8 to 198.0 ng/mL, and high levels correlated significantly with lymph node metastasis and lower overall survival. These findings position osteopontin as a promising tumor biomarker whose translational value depends on high-sensitivity, high-specificity antibody reagents.

Antibody Development and Quality Control Evolution

The evolution of osteopontin antibody technology reflects broader progress in antibody engineering, advancing from early polyclonal reagents through high-specificity monoclonal antibodies to genetically engineered humanized formats, with each generation improving performance and application range. Traditional preparation immunized animals such as rabbits, mice, or goats with purified recombinant osteopontin protein to obtain polyclonal antiserum. That approach is simple and economical yet suffers from substantial batch variation and comparatively low specificity, and in immunohistochemical applications it frequently produces deep background staining and elevated false-positive rates. Hybridoma technology enabled monoclonal antibody production by fusing spleen cells from immunized mice with myeloma cells and screening hybridoma lines that stably secrete specific antibodies, yielding reagents with high homogeneity and specificity.

Modern recombinant antibody technology has advanced the field further. Genetic engineering allows researchers to graft complementarity-determining regions from murine antibodies onto human antibody frameworks, generating humanized or fully human osteopontin antibodies with greatly reduced immunogenicity. Expression systems have shifted from early hybridoma supernatant production to large-scale culture in mammalian systems such as CHO cells, ensuring glycosylation patterns closer to native human antibodies. Quality control has likewise matured, with modern preparation achieving purity above ninety percent and endotoxin levels controlled below 0.002 EU per microgram. Typical characterization covers isotype identification, most commonly IgG1 or IgG2a, titre determination, specificity verification by Western blot, immunohistochemistry, and immunofluorescence, affinity measurement with equilibrium dissociation constants in the nanomolar range, and cross-reactivity assessment. Functional testing varies by intended application, with neutralizing activity required for research antibodies intended to block signaling and detection sensitivity specified for reagents intended for quantification.

Product Enablement from ANT BIO PTE. LTD.

ANT BIO PTE. LTD. supplies research reagents for osteopontin detection and functional study. The OPN1SW Rabbit Polyclonal Antibody (S0B1498) provides broad reactivity suitable for Western blot, immunohistochemistry, and related protein detection workflows in tumor tissue and cell line models. Recombinant proteins complement antibody-based detection by supplying defined standards and control antigens. The OPN/SPP1 His Tag Protein, Human (UA010434) and OPN/SPP1 His Tag Protein, Mouse (UA010469) are both expressed in HEK293 host cells, preserving mammalian folding and post-translational modification patterns that support physiological relevance in binding studies. Together these reagents support assay calibration, antibody validation, functional binding experiments, and cross-species comparative research in the tumor microenvironment, with all applications restricted to basic research.

Related Products

ANT BIO PTE. LTD. – Empowering Scientific Breakthroughs

At ANTBIO, we are committed to advancing life science research through high-quality, reliable reagents and comprehensive solutions. Our specialized sub-brands (Starter, Absin, UA) cover a full spectrum of research needs, from general reagents and kits to antibodies and recombinant proteins. With a focus on innovation, quality, and customer-centricity, we strive to be your trusted partner in unlocking scientific mysteries and driving medical progress. Explore our product portfolio today and elevate your research to new heights.

Disclaimer

This article was partially created with the assistance of artificial intelligence. If any content involves copyright or intellectual property issues, please inform us, and we promise to verify and remove it immediately.